ClinicalTrials.gg
RecruitingNCT07435467BAD-GERUpdated Feb 27, 2026

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

An observational study in Alzheimer Disease and Old Age; Dementia, sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. Recruiting at 3 sites in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Istituto Nazionale di Ricovero e Cura per Anziani · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
400
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Planned enrollment
12th of 36
400 · median 273
Started
2025
with 22 others
Observational
36 of 206
18 open now
Primary completion
2026-06
later than 18 of 71 live
Registered
192nd of 206
by date
Lead sponsor
5 of 206
Istituto Nazionale di Ricovero e Cura per Anziani

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 12th largest by planned enrollment of the 36 observational ones that give a count, is one of 23 that started in 2025, is one of 36 observational ones, reaches primary completion later than 18 of the 71 other live ones, and was the 192nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.

Read the detailed description

Blood levels of amyloid ß-42 (Aß42), total and phosphorylated tau protein (t- and p-tau) associated with other biomarkers of neuro-injury, i.e. neurofilament light (NfL) chain and with biomarkers of neuroinflammation, such as CXCL8, CXCL12 and glial fibrillary acidic protein (GFAP), and metabolites analyzable with metabolomic approach, can provide information not only on neuro-injury, but also on risk of re-hospitalization and mortality. The investigators called these biomarkers BAD-GER biomarkers. The BAD-GER study is a multicenter, prospective, three-arm observational study designed to validate a prognostic biomarker algorithm for mortality and hospital readmission. This algorithm will be derived from a retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers within an existing discovery cohort of 700 geriatric patients. By integrating clinical data, routine laboratory parameters, immunophenotypes, and specific BAD-GER biomarkers into a minimal dataset, the study will assess associations with functional/cognitive status, as well as short-term and one-year mortality and rehospitalization rates.

03

Conditions studied

  • Alzheimer Disease
  • Old Age; Dementia

Keywords

  • aging
  • geriatric
  • biomarkers
  • inflammation
  • neurodegeneration
  • mortality
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Older inpatients.

Eligibility criteria

GROUP 1: Patients hospitalized for acute neurological disorders

Inclusion criteria:

  • Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis

Exclusion criteria:

  • no

GROUP 2: Patients hospitalized for non-neurological diseases with dementia

Inclusion criteria:

  • inpatients with diagnosis of major neurocognitive disorder according to criteria (2013)

Exclusion criteria:

  • Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
  • no informed consent

GROUP 3: Patients hospitalized for non-neurological diseases without dementia

Inclusion criteria:

  • inpatients with non-neurological diseases

Exclusion criteria:

  • inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
  • diagnosis of dementia
  • no informed consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients hospitalized for acute neurological disorders

    Inpatients with one of the following diagnosis: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis

    Other: collection of blood samples

  • Patients hospitalized for non-neurological diseases with dementia

    Inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013)

    Other: collection of blood samples

  • Patients hospitalized for non-neurological diseases without dementia

    Inpatients with non-neurological diseases without dementia

    Other: collection of blood samples

Interventions

  • Othercollection of blood samples

    Serum and EDTA-plasma samples will be collected at baseline

06

What researchers measure

Primary outcomes

  1. All-cause Mortality

    To validate the prognostic value of a biomarker algorithm derived from a retrospective analysis of Alzheimer's disease and neurodegeneration biomarkers within an existing discovery cohort of 700 geriatric inpatients.

    Time frame: 12 months from enrollment

  2. Number of hospital readmission

    To validate the prognostic value of a biomarker algorithm derived from a retrospective analysis of Alzheimer's disease and neurodegeneration biomarkers within an existing discovery cohort of 700 geriatric inpatients.

    Time frame: 12 months from enrollment

Secondary outcomes

  1. Comprehensive geriatric assessment by INTERRAI-MDS-AC/VAOR-AC instrument

    Identification information, personal data at admission, assessment date, cognitive function, communication and vision, mood and behaviour, physical function, incontinence, diagnosis of the disease, health conditions, oral and nutrition status, skin conditions, medications, treatment and procedures, advanced directives, discharge potential, discharge, assessment information, anamnestic-clinical data, standardised clinical assessment, physical performance tests

    Time frame: At baseline

  2. Levels of amyloid ß-42

    The levels of plasma amyloid ß-42 (Aß42) are assessed.

    Time frame: At baseline

  3. Assessment of cognitive function

    Cognitive function will be assessed using the Mini Mental State Examination (MMSE). Score ranges 0-30, with higher score indicating better cognitive function.

    Time frame: At baseline

  4. Assessment of cognition

    Clinical Dementia Rating Scale (CDR) is a cognitive test that is used to assess the severity of dementia. It evaluates six cognitive and functional domains, where the scores are summed to provide a total score from 0 (no cognitive impairment) to 30 (severe impairment).

    Time frame: At baseline

  5. Assessment of frailty

    It will be assessed by the Clinical Frailty Scale (CFS). This descriptive scale divides the older participants into 9 classes based on the information provided by them and their relatives: between 1 and 3 the patient is non-frail, pre-frail if 4, he is frail from 5 to 9.

    Time frame: At baseline

  6. Levels of tau proteins

    Plasma levels of total tau (t-tau) and phosphorylated tau (p-tau) will be quantified.

    Time frame: At baseline

  7. Marker of neuro-injury

    Neurofilament light chain (NfL) levels will be assessed in plasma

    Time frame: At baseline

  8. Neuroinflammation

    The plasma pro-inflammatory chemokine CXCL8 (Interleukin-8) and the homeostatic chemokine CXCL12 (SDF-1) will be measured

    Time frame: At baseline

  9. Marker of astrocyte activation

    Plasma concentrations of glial fibrillary acidic protein (GFAP) will be quantified

    Time frame: At baseline

07

Study locations

3 of 3 sites recruiting
  • IRCCS INRCA Hospital
    Ancona, Italy
    Recruiting
    • Antonio Cherubini, MD · Principal investigator
    • Riccardo Sarzani, MD · Principal investigator
    • Leonardo Biscetti, MD · Principal investigator
  • IRCCS INRCA Hospital
    Fermo, Italy
    Recruiting
    • Cinzia Giuli, PhD · Contact
    • Roberto Brunelli, MD · Principal investigator
  • Policlinico Universitario
    Messina, Italy
    Recruiting
    • Paolino La Spina, MD · Contact
    • Paolino La Spina, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 14 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 27, 2026
StartActual
Apr 9, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07435467
Lead sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators
Ministry of Health, Italy, University of Salento, IRCCS Multimedica, Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 9, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Anna Rita Bonfigli
Contact
a.bonfigli@inrca.it
+390718003719
Fabiola Olivieri, Professor
study chair · IRCCS INRCA, Ancona, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion